Even a notoriously forgiving Wall Street won’t touch Martin Shkreli with a 10-foot poll.

A company controlled by Shkreli — the notorious pharmaceutical chief executive arrested by the FBI Thursday for allegedly running a “Ponzi-like” stock scheme — was halted indefinitely from trading after crashing more than 50 percent before the market opened.

The reaction from Wall Street was a sure sign Shkreli, 32, was nearly as toxic as a bundle of subprime home loans.

Shares of Shkreli’s KaloBios Pharmaceuticals traded as low as $11.03 on Nasdaq after falling more than 53 percent.

The halving of the company stock has already lost Shkreli at least $40 million from the stock’s high point on Nov. 23, though his 50 percent stake in the company could be as good as worthless.

Shkreli is also the CEO of Turing Pharmaceuticals, which makes Daraprim. Shkreli first gained infamy after jacking up the price of the drug, which can be lifesaving for AIDS and cancer patients, by 5,500 percent overnight.

Nasdaq had KaloBios on its delisting watch list since it flirted with bankruptcy in November, said a person familiar with the mart’s deliberations.

It’s possible that the company could never be traded publicly again.
The reaction was ironic, since Shkreli was pressuring bearish investors on the company.

The tarnished CEO, who pleaded not guilty and was released on $5 million bail, became the head of the obscure pharma company in November after buying up shares while it teetered on the edge of bankruptcy.

That sent its shares to $45, up from just 44 cents, in a matter of a few days.

But those bearish investors, who borrow stock and sell it, betting the price is about to plunge, will likely laugh last.

Edward Painter, a spokesman for both Turing and KaloBios, didn’t return calls for comment.